chronic hyperkalaemia
Endocrinology · 2019–2024
2decisions
2medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sodium zirconium cyclosilicate Treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3-4 who are receiving or indicated for renin angiotensin aldosterone system… | Mar 2024 | Recommended with restriction | input received |
| patiromer Initial and continuing treatment of chronic hyperkalaemia in patients with CKD Stage 3+ who are receiving or indicated for renin-angiotensin-aldosterone system… | Nov 2019 | Not recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.